Home > Back to Publisher > Report Information

Turkey In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2017

Global Markets Direct
January 23, 2012
146 Pages - SKU: GMD6775775

Abstract Table of Contents Search inside this report Related Reports

Countries covered: Turkey

Turkey In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2017

Summary

”Turkey In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2017”, a new report by Global Markets Direct, provides key market data on the Turkey In Vitro Diagnostics market. The report provides value (USD million) data for each segment and sub-segment within seven market categories - Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on key recent developments.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Global Markets Direct’s team of industry experts.

Scope

Market size and company share data for In Vitro Diagnostics market categories - Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture.
Annualized market revenues (USD million) data for each of the segments and sub-segments within seven market categories. Data from 2003 to 2010, forecast forward for 7 years to 2017.
2010 company shares and distribution shares data for each of the seven market categories.
Global corporate-level profiles of key companies operating within the Turkey In Vitro Diagnostics market.
Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Abbott Laboratories, Beckman Coulter, Inc., bioMerieux S.A., Ortho-Clinical Diagnostics Inc. and others.

Reasons to buy

Develop business strategies by identifying the key market categories and segments poised for strong growth.
Develop market-entry and market expansion strategies.
Design competition strategies by identifying who-stands-where in the Turkey In Vitro Diagnostics competitive landscape.
Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
What are the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.

1 Table of Contents: 1.1 List of Tables; 1.2 List of Figures
2 Introduction: 2.1 What is This Report About?
3 In Vitro Diagnostics In Turkey: 3.1 In Vitro Diagnostics, Turkey, Overall Revenue ($m), USD Actual, 2003-2017; 3.2 In Vitro Diagnostics, Turkey, Company share (2009-2010)
4 Clinical Chemistry In Turkey: 4.1 Clinical Chemistry Overall Revenue (2003-2017); 4.2 Clinical Chemistry Distribution Share (2009-2010); 4.3 Clinical Chemistry, Turkey, Company share (2009-2010)
5 Genetic Testing In Turkey: 5.1 Genetic Testing Overall Revenue (2003-2017); 5.2 Genetic Testing Distribution Share (2009-2010); 5.3 Genetic Testing, Turkey, Company share (2009-2010)
6 Haematology In Turkey: 6.1 Haematology Overall Revenue (2003-2017); 6.2 Haematology Distribution Share (2009-2010); 6.3 Haematology, Turkey, Company share (2009-2010)
7 Histology And Cytology In Turkey: 7.1 Histology And Cytology Overall Revenue (2003-2017); 7.2 Histology And Cytology Distribution Share (2009-2010); 7.3 Histology And Cytology, Turkey, Company share (2009-2010)
8 Immuno Chemistry In Turkey: 8.1 Immuno Chemistry Overall Revenue (2003-2017); 8.2 Immuno Chemistry Distribution Share (2009-2010); 8.3 Immuno Chemistry, Turkey, Company share (2009-2010)
9 Infectious Immunology In Turkey: 9.1 Infectious Immunology Overall Revenue (2003-2017); 9.2 Infectious Immunology Distribution Share (2009-2010); 9.3 Infectious Immunology, Turkey, Company share (2009-2010)
10 Microbiology Culture In Turkey: 10.1 Microbiology Culture Overall Revenue (2003-2017); 10.2 Microbiology Culture Distribution Share (2009-2010); 10.3 Microbiology Culture, Turkey, Company share (2009-2010)
11 Overview of Key Companies in Turkey In Vitro Diagnostics Market: 11.1 F. Hoffmann-La Roche Ltd.; 11.2 Siemens Healthcare; 11.3 Abbott Laboratories; 11.4 Beckman Coulter, Inc.; 11.5 bioMerieux S.A.; 11.6 Ortho-Clinical Diagnostics Inc.; 11.7 Sysmex Corporation; 11.8 Bio-Rad Laboratories, Inc.; 11.9 Becton, Dickinson and Company; 11.10 Phadia AB; 11.11 DiaSorin S.p.A; 11.12 Danaher Corporation; 11.13 DIAGNOSTICA STAGO, Inc.; 11.14 Thermo Fisher Scientific Inc.; 11.15 HORIBA, Ltd.; 11.16 Qiagen N.V.; 11.17 PerkinElmer, Inc.; 11.18 Grifols, S.A.; 11.19 Life Technologies Corporation; 11.20 Gen-Probe Incorporated; 11.21 Immucor, Inc.; 11.22 Mindray Medical International Limited; 11.23 Hologic, Inc.; 11.24 Cellestis Limited
12 Financial Deals Landscape: 12.1 Acquisition; 12.2 Partnerships
13 Appendix: 13.1 Global Markets Direct Research Methodology; 13.2 Definitions of Markets Covered in the Report; 13.3 Secondary Research; 13.4 Primary Research; 13.5 Models; 13.6 Forecasts; 13.7 Expert Panel Validation; 13.8 Currency Conversion; 13.9 Contact Us; 13.10 Disclaimer
1.1 List of Tables: Table 1: In Vitro Diagnostics, Turkey, Overall Revenue ($m), USD Actual, 2003-2017; Table 2: In Vitro Diagnostics, Turkey, Overall Revenue ($m), USD Actual, Historic, 2003-2010; Table 3: In Vitro Diagnostics, Turkey, Overall Revenue ($m), USD Actual, Forecast, 2010-2017; Table 4: In Vitro Diagnostics, Turkey, Company share by Revenue ($m), USD Actual, 2009-2010; Table 5: Clinical Chemistry, Turkey, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Table 6: Clinical Chemistry, Turkey, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Table 7: Clinical Chemisty Analyzers, Turkey, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 8: Clinical Chemisty Analyzers, Turkey, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 9: Urine Analysis, Turkey, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 10: Urine Analysis, Turkey, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 11: Clinical Chemistry, Turkey, Distribution Share by Revenue ($m), USD Actual, 2009-2010; Table 12: Clinical Chemistry, Turkey, Company share by Revenue ($m), USD Actual 2009-2010; Table 13: Genetic Testing, Turkey, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Table 14: Genetic Testing, Turkey, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Table 15: Genetic Testing, Turkey, Distribution Share by Revenue ($m), USD Actual, 2009-2010; Table 16: Genetic Testing, Turkey, Company share by Revenue ($m), USD Actual 2009-2010; Table 17: Haematology, Turkey, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Table 18: Haematology, Turkey, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Table 19: Haematology Reagents, Turkey, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 20: Haematology Reagents, Turkey, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 21: Immunohaematology, Turkey, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 22: Immunohaematology, Turkey, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 23: Haemostasis, Turkey, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 24: Haemostasis, Turkey, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 25: Haematology Rapid Tests, Turkey, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 26: Haematology Rapid Tests, Turkey, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 27: Haematology Cell Counters, Turkey, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 28: Haematology Cell Counters, Turkey, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 29: Haematology, Turkey, Distribution Share by Revenue ($m), USD Actual, 2009-2010; Table 30: Haematology, Turkey, Company share by Revenue ($m), USD Actual 2009-2010; Table 31: Histology And Cytology, Turkey, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Table 32: Histology And Cytology, Turkey, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Table 33: Histology And Cytology, Turkey, Distribution Share by Revenue ($m), USD Actual, 2009-2010; Table 34: Histology And Cytology, Turkey, Company share by Revenue ($m), USD Actual 2009-2010; Table 35: Immuno Chemistry, Turkey, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Table 36: Immuno Chemistry, Turkey, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Table 37: Disease Specific Immunochemistry, Turkey, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 38: Disease Specific Immunochemistry, Turkey, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 39: Drugs of Abuse / Toxicology, Turkey, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 40: Drugs of Abuse / Toxicology, Turkey, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 41: Endocrinology Tests, Turkey, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 42: Endocrinology Tests, Turkey, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 43: Therapeutic Drug Monitoring, Turkey, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 44: Therapeutic Drug Monitoring, Turkey, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 45: Immunochemistry Analyzers, Turkey, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 46: Immunochemistry Analyzers, Turkey, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 47: Immuno Chemistry, Turkey, Distribution Share by Revenue ($m), USD Actual, 2009-2010; Table 48: Immuno Chemistry, Turkey, Company share by Revenue ($m), USD Actual 2009-2010; Table 49: Infectious Immunology, Turkey, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Table 50: Infectious Immunology, Turkey, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Table 51: Infectious Immunology, Turkey, Distribution Share by Revenue ($m), USD Actual, 2009-2010; Table 52: Infectious Immunology, Turkey, Company share by Revenue ($m), USD Actual 2009-2010; Table 53: Microbiology Culture, Turkey, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Table 54: Microbiology Culture, Turkey, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Table 55: Microbiology Analyzers, Turkey, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 56: Microbiology Analyzers, Turkey, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 57: Microbiology Culture, Turkey, Distribution Share by Revenue ($m), USD Actual, 2009-2010; Table 58: Microbiology Culture, Turkey, Company share by Revenue ($m), USD Actual 2009-2010; Table 59: ERBA DIAGNOSTICS MANNHEIM Acquires Diasis Diagnostic Systems; Table 60: Biofortuna Enters Into Distribution Agreement With Abbott; Table 61: Trinity Biotech Enters Into Distribution Agreement With A. Menarini Diagnostics; Table 62: USD to Local Currency, Turkey, Average Actual Rate 2003-2010
1.2 List of Figures: Figure 1: In Vitro Diagnostics, Turkey, Overall Revenue ($m), USD Actual, 2003-2017; Figure 2: In Vitro Diagnostics, Turkey, Overall Revenue ($m), USD Actual, Historic, 2003-2010; Figure 3: In Vitro Diagnostics, Turkey, Overall Revenue ($m), USD Actual, Forecast, 2010-2017; Figure 4: In Vitro Diagnostics, Turkey, Company share (%), 2010; Figure 5: Clinical Chemistry, Turkey, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Figure 6: Clinical Chemistry, Turkey, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Figure 7: Clinical Chemisty Analyzers, Turkey, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 8: Clinical Chemisty Analyzers, Turkey, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 9: Urine Analysis, Turkey, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 10: Urine Analysis, Turkey, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 11: Clinical Chemistry, Turkey, Company share (%), 2010; Figure 12: Genetic Testing, Turkey, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Figure 13: Genetic Testing, Turkey, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Figure 14: Genetic Testing, Turkey, Company share (%), 2010; Figure 15: Haematology, Turkey, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Figure 16: Haematology, Turkey, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Figure 17: Haematology Reagents, Turkey, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 18: Haematology Reagents, Turkey, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 19: Immunohaematology, Turkey, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 20: Immunohaematology, Turkey, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 21: Haemostasis, Turkey, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 22: Haemostasis, Turkey, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 23: Haematology Rapid Tests, Turkey, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 24: Haematology Rapid Tests, Turkey, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 25: Haematology Cell Counters, Turkey, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 26: Haematology Cell Counters, Turkey, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 27: Haematology, Turkey, Company share (%), 2010; Figure 28: Histology And Cytology, Turkey, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Figure 29: Histology And Cytology, Turkey, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Figure 30: Histology And Cytology, Turkey, Company share (%), 2010; Figure 31: Immuno Chemistry, Turkey, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Figure 32: Immuno Chemistry, Turkey, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Figure 33: Disease Specific Immunochemistry, Turkey, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 34: Disease Specific Immunochemistry, Turkey, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 35: Drugs of Abuse / Toxicology, Turkey, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 36: Drugs of Abuse / Toxicology, Turkey, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 37: Endocrinology Tests, Turkey, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 38: Endocrinology Tests, Turkey, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 39: Therapeutic Drug Monitoring, Turkey, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 40: Therapeutic Drug Monitoring, Turkey, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 41: Immunochemistry Analyzers, Turkey, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 42: Immunochemistry Analyzers, Turkey, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 43: Immuno Chemistry, Turkey, Company share (%), 2010; Figure 44: Infectious Immunology, Turkey, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Figure 45: Infectious Immunology, Turkey, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Figure 46: Infectious Immunology, Turkey, Company share (%), 2010; Figure 47: Microbiology Culture, Turkey, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Figure 48: Microbiology Culture, Turkey, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Figure 49: Microbiology Analyzers, Turkey, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 50: Microbiology Analyzers, Turkey, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 51: Microbiology Culture, Turkey, Company share (%), 2010; Figure 52: Global Markets Direct Methodology

More Turkey Reports

D&B Country RiskLine Report: Turkey by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

Country Report Turkey February 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...

D&B Country Report: Turkey by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...

Turkey This Week by Intellinews
Weekly report on the most significant economic, business, financial markets and political issues and events propelling the Turkey's ...

Country Report Turkey January 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...

See all reports like this >>

Turkey In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2017

Share this report

Other tasks

Research Assistance

Related Markets

Hematology & Oncology Reports

Free Alert Me service